# Pierre Bédossa

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/pierre-bedossa/

## Facts

| Field | Value |
| --- | --- |
| Citations | 72,233 |
| Field | Liver Disease Diagnosis and Treatment |
| h-index | 122 |
| i10-index | 400 |
| Last Known Institution | Université Sorbonne Paris Nord |
| OpenAlex ID | https://openalex.org/A5038609111 |
| ORCID iD | https://orcid.org/0000-0002-8487-7322 |
| Works | 888 |

## Researcher papers

Showing 12 of 22.

- [A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement](https://scholariq.org/papers/a-new-definition-for-metabolic-dysfunction-associated-fatty-liver-disease-an/)
- [MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease](https://scholariq.org/papers/mafld-a-consensus-driven-proposed-nomenclature-for-metabolic-associated-fatty/)
- [A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis](https://scholariq.org/papers/a-phase-3-randomized-controlled-trial-of-resmetirom-in-nash-with-liver-fibrosis/)
- [NASH limits anti-tumour surveillance in immunotherapy-treated HCC](https://scholariq.org/papers/nash-limits-anti-tumour-surveillance-in-immunotherapy-treated-hcc/)
- [Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial](https://scholariq.org/papers/obeticholic-acid-for-the-treatment-of-non-alcoholic-steatohepatitis-interim/)
- [Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening](https://scholariq.org/papers/elafibranor-an-agonist-of-the-peroxisome-proliferator-activated-receptor-and/)
- [FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study](https://scholariq.org/papers/fibroscan-ast-fast-score-for-the-non-invasive-identification-of-patients-with/)
- [A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH](https://scholariq.org/papers/a-randomized-controlled-trial-of-the-pan-ppar-agonist-lanifibranor-in-nash/)
- [Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis](https://scholariq.org/papers/insulin-resistance-in-chronic-hepatitis-c-association-with-genotypes-1-and-4/)
- [Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆](https://scholariq.org/papers/genome-wide-association-study-of-non-alcoholic-fatty-liver-and-steatohepatitis/)
- [Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis](https://scholariq.org/papers/transcriptomic-profiling-across-the-nonalcoholic-fatty-liver-disease-spectrum/)
- [Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-elastography-and-magnetic-resonance-imaging-in-patients/)

## Researcher topics

- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)
- [Hepatitis C virus research](https://scholariq.org/topics/hepatitis-c-virus-research/)
- [Liver Disease and Transplantation](https://scholariq.org/topics/liver-disease-and-transplantation/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Liver Diseases and Immunity](https://scholariq.org/topics/liver-diseases-and-immunity/)

## Researcher university

- [Université Sorbonne Paris Nord](https://scholariq.org/institutions/universite-sorbonne-paris-nord/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.